We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Detecto

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
16 Feb 2023 - 18 Feb 2023

Groundbreaking Technology Radically Improves Minimally Invasive Endoscopic Surgery

By HospiMedica International staff writers
Posted on 11 Jan 2023
Print article
Image: EndoTheia has received FDA Breakthrough Device Designation for its technology to improve endoscopic surgery (Photo courtesy of EndoTheia)
Image: EndoTheia has received FDA Breakthrough Device Designation for its technology to improve endoscopic surgery (Photo courtesy of EndoTheia)

A next-generation endoscope technology aims to radically improve minimally invasive flexible endoscopic surgery by harnessing the power of intelligently micro-machined smart materials to create highly dexterous manipulators at millimeter and sub-millimeter scales, thereby enhancing therapeutic outcomes.

The disruptive platform technology from EndoTheia Inc. (Nashville, TN, USA), based on extremely thin-walled, laser-machined metallic tubes, enables the creation of highly flexible, steerable devices that can pass through standard endoscopes, while also carrying within themselves interventional tools. The steerability that these devices provide to endoscope-delivered tools opens the door for new diagnostic and therapeutic applications of flexible endoscopy. The technology can be used across a vast array of clinical specialties, including urology, gastroenterology, neurology, and otology.

EndoTheia’s proprietary technology exploits pre-programmed mechanical properties in concentric super-elastic tubes to enable tool steerability at the tips of flexible endoscopes without any modification to the endoscope itself. This eliminates parasitic bending along the instrument length like with tendon-actuated systems. By doing away with pullwires and discrete linkages, EndoTheia can create steerable tools with thinner walls and smaller diameters than ever before. It is this capability that allows the company to create dexterous instruments all the way down to 2F in diameter, with an open lumen allowing for the passage of adjunct tools, fluid flow, or suction/irrigation, adding value to the most demanding endoscopic applications. Coupling EndoTheia’s steerable tips with proprietary insertion shaft technology enables distal dexterity at the most demanding of curvatures and deflection angles, with high torsional trackability, axial stiffness, and bidirectional steerability.

EndoTheia has gained priority status from the FDA by receiving a Breakthrough Device designation from the agency for its next-generation endoscope technology. EndoTheia has demonstrated feasibility in animal, cadaver, and tissue model studies in surgeries for biliary disease, ureteroscopy kidney stone removal, endoscopic submucosal dissection (ESD), endoscopic neurosurgery, sinus surgery, and middle ear surgery. EndoTheia’s technology can provide dexterity in any procedures where tools are delivered through flexible endoscopes, including urology, neurology, interventional pulmonology, gastroenterology, colorectal, orthopedics, otolaryngology (ENT), and other sub-specialties.

“EndoTheia’s technology is currently the only viable option to add dexterity to flexible endoscopy, without re-engineering the endoscope itself,” said Robert J. Webster, III, PhD, Co-Founder and President of EndoTheia. “This empowers surgeons to provide much more accurate and precise therapeutic interventions in a wide range of clinical specialties.”

“We are excited that the FDA has recognized the huge potential of EndoTheia’s technology through Breakthrough Device designation,” added S. Duke Herrell, III, MD, FACS, Co-Founder and Chief Medical Officer of EndoTheia. “The FDA has affirmed our view that there is nothing else out there capable of doing what we do for flexible endoscopy, and that our technology represents a breakthrough treatment option for patients who currently face irreversibly debilitating disease.”

Related Links:
EndoTheia Inc. 

Gold Supplier
Temperature Monitor
ThermoScan Temperature Monitoring Unit
New
Smart nCPAP Device
SVAAS nCPAP
New
Analgesic Gas Delivery System
O-Two Equinox Advantage
New
Double-Door Pass-Through Autoclave
150L - 700L Double-Door / Pass-Through

Print article

Channels

AI

view channel
Image: A novel research study moves the needle on predicting coronary artery disease (Photo courtesy of Pexels)

AI-Enabled ECG Analysis Predicts Heart Attack Risk Nearly as well as CT Scans

Increased coronary artery calcium is a marker of coronary artery disease that can lead to a heart attack. Traditionally, CT scans are used to diagnose buildup of coronary artery calcium, although CT scanners... Read more

Critical Care

view channel
Image: The new biomaterial heals tissues from the inside out (Photo courtesy of UC San Diego)

Groundbreaking Biomaterial Injected Intravenously Repairs Cells and Tissue Damaged by Heart Attack and TBI

Following a heart attack, there is development of scar tissue, which affects muscle function and can result in congestive heart failure. However, there is still no established treatment available for repairing... Read more

Health IT

view channel
Image: Using digital data can improve health outcomes (Photo courtesy of Unsplash)

Electronic Health Records May Be Key to Improving Patient Care, Study Finds

When a patient gets transferred from a hospital to a nearby specialist or rehabilitation facility, it is often difficult for personnel at the new facility to access the patient’s electronic health records... Read more

Point of Care

view channel
Image: Steripath improves the diagnostic accuracy and timeliness of sepsis test results (Photo courtesy of Magnolia)

All-in-One Device Reduces False-Positive Diagnostic Test Results for Bloodstream Infections

Blood cultures are considered the gold standard diagnostic test for the detection of blood stream infections, such as sepsis. However, positive blood culture results can be frequently wrong, and about... Read more

Business

view channel
Image: The global patient positioning systems market is projected to reach USD 1.7 billion by 2027 (Photo courtesy of Pexels)

Global Patient Positioning Systems Market Driven by Increasing Chronic Diseases

The global patient positioning systems market is projected to grow at a CAGR of 4% from USD 1.4 billion in 2022 to USD 1.7 billion by 2027, driven by increasing technological advancements in medical devices,... Read more
Copyright © 2000-2023 Globetech Media. All rights reserved.